Interleukin-7 and Interleukin-15 for Cancer
Open Access
- 1 January 2014
- journal article
- review article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 5 (9) , 765-773
Abstract
Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer.Keywords
This publication has 95 references indexed in Scilit:
- IFNγ in combination with IL-7 enhances immunotherapy in two rat glioma modelsJournal of Neuroimmunology, 2013
- Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for ImmunotherapyPLOS ONE, 2012
- Interleukin-15 biology and its therapeutic implications in cancerTrends in Pharmacological Sciences, 2012
- Dose Finding Study for the Use of Subcutaneous Recombinant Interleukin-2 to Augment Natural Killer Cell Numbers in an Outpatient Setting for Stage 4 Neuroblastoma After Megatherapy and Autologous Stem-Cell ReinfusionJournal of Clinical Oncology, 2011
- Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapyClinical Immunology, 2007
- Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrixBlood, 2002
- Pre-B Cell Receptor Signaling Mediates Selective Response to IL-7 at the Pro-B to Pre-B Cell Transition via an ERK/MAP Kinase-Dependent PathwayImmunity, 2001
- Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines.2000
- Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7Vaccine, 2000
- Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptorNature, 1998